Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Rehovot Israel and postdoctoral NIH, USA and UCLA School of Medicine. She is the director of Molecular Microbiology laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Beer Sheva, Israel. He has published more than 65 papers in reputed journals.
Yaffa Mizrachi Nebenzahl(Research Area)
Yaffa Mizrachi Nebenzahl research expertise is on Biochemical and molecular viral and bacterial biology, Cell biology, Viral and bacterial pathogenesis, Innate and adaptive immune response to pathogens
Harry W Schroeder Jr completed his MD PhD at the age of 28 years from Baylor College of Medicine. He then completed residency in Internal Medicine at the age of 31 at the University of Kentucky, fellowship in Medical Genetics at the University of Washington, postdoctoral studies at the Howard Hughes Medical Institute at the University of Washington, and a sabbatical year at the Institute for Genetics at the University of Cologne. He is the director of the Program in Immunology at the University of Alabama at Birmingham,. He has published more than 120 papers in reputed journals and has served as an editorial board member several journals of repute.
Harry W. Schroeder(Research Area)
Harry W. Schroeder research expertise is on B cell and repertoire development and Genetics of primary immune deficiency diseases.
Reinhard Pabst is the Professor of Institute for Immunomorphology, Centre of Anatomy Medical School Hannover, Germany. 2002 to 2006 he was Dean for Research at Medical School Hannover. He was Head of Institute of Functional and Applied Anatomy 1992 to 2009. From 2009 to 2015 he was Senior Research Prof. in Immunohistology.
Reinhard Pabst(Research Area)
Reinhard Pabst research expertise is on lymphocyte migration, bone marrow, Regeneration of auto transplanted fragments of lymph nodes.
Marcus Saemann is Head of the 6th Medical Department with Nephrology and Dialysis, Wilhelminenspital Vienna, Austria.
Previously, he was senior consultant nephrologist, at the Medical University of Vienna, Austria. He has more than 15 years of experience in all branches of nephrology including the whole spectrum of clinical nephrology, acute kidney injury, chronic kidney diseases, kidney transplantation, kidney-pancreas transplantation, intensive care nephrology, all extracorporal strategies such as hemodialysis, hemofiltration, peritoneal dialysis, along with plasmapheresis including immunoadsorption. Further clinical focus is the treatment of both type 1 and 2 diabetes mellitus especially with chronic kidney disease (diabetic kidney disease).
Marcus Saemann(Research Area)
Marcus Saemann research interest is on Diabetic kidney disease including Renin-Angiotensin-Aldosteron-System, HDL Cholesterol in Chronic Kidney Disease, Post-Transplant Diabetes mellitus,Diabetes management including insulin pump and continuous glucose measurement (CGM) technology (artificial pancreas, Immunosuppression after renal transplantation, especially mTOR inhibition, CMV infection, Urinary tract infection
Dr. Chentoufi is Diplomate of the American Board of Medical laboratory Immunology D (ABMLI ), he is Fellow of the Association of Clinical Sciences (FACSc) and Fellow of the Academy of Translational Medicine (FAcadTM). He is Consultant & Head of Immunology/Serology/HLA section at Pathology and Clinical Laboratory Medicine (PCLMA) at KFMC. He is also Assistant Professor of Immunology at the King Saud Ibn AbdulAziz University FOM-KFMC. He is the Chairperson of Research Committee of PCLMA, KFMC. He received his Ph.D. in BioMedical Sciences from the University Catholic of Louvain, Brussels, Belgium in 1999. Dr Chentoufi has done postdoctoral fellowship at McGill University, Montreal, Canada from 1999 to 2004 where he worked on immunogenetic of type 1 Diabetes and gene therapy for graft versus host disease.Dr Chentoufi is associate editors in many scientific journals and has more than 50 publications in high impact factor journals.
Aziz A. Chentoufi(Research Area)
Aziz A. Chentoufi research interest is on development of mucosal vaccine against herpes simplex virus type 1 and 2, immunogenetic of type 1 Diabetes and gene therapy for graft versus host disease.
Dr. Rongtuan Lin is Associate Professor - Department of Medicine, Division of Experimental Medicine. He has published more than 20 papers in differebt journals. he is involved in many projects such as Regulation of the interferon antiviral defense pathway, Small molecule agonists of the RIG-I pathway as innate stimulatory agents against virus infection, Combination oncolytic virotheapy for the treatment of prostate cancer.
Rongtuan Lin(Research Area)
Dr. Rongtuan Lin research interest is on Innate Immunity, Interferon Sginaling, Viral Evasion.
Dr. Kwon had his PhD from the Georgia Regents University, in 1981 and postdoctoral studies at the Department of Human Genetics, Yale University from 1981 to 1984. Dr. Kwon was a tenured Professor of the Indiana University School of Medicine, a Professor and Director of the Immunomodulation Research Center at the University of Ulsan, a Distinguished Professor and Investigator at the National Cancer Center, Korea, and Professor at the Department of Medicine Tulane University, New Orleans LA . He is currently the Founder and CEO of Eutilex who is developing T cell therapeutics and immunomodulatory antibody therapeutics. He has published over 300 peer-reviewed papers and has been serving as an editorial member of reputable journals.
Byoung S. Kwon(Research Area)
Byoung S. Kwon research expertise is focuses on immunotherapy against cancers and autoimmune diseases. Dr. Kwon has established a concept called â€œinducible costimulationâ€ by discovering 4-1BB-4-1BBL and AITR-AITRL systems. He has proved that immune functions can be selectively suppressed or enhanced through the inducible costimulation and presented the possibility of â€œselective immunotherapyâ€. Antigen-specific T cell therapeutics that Dr. Kwonâ€™s team has developed are in phase 1 trials against various cancers in the NCC.